Speaker Profile
Ph.D., Vice President of Assay Development, Xilis
Biography
Kendra is leading assay development efforts at Xilis, Inc., working to establish and implement assays using ex vivo patient tumor models generated with the Xilis MicroOrganoSpheres Technology. Kendra has over 20 years of pharmaceutical industry experience spanning from research and development to manufacturing and from small biotech to large pharma companies. During this time, she has established a broad foundation in the biological and chemical sciences and has made significant contributions to a wide range of assets, technologies, targets, modalities, and therapeutic areas. A particular area of focus for Kendra has been developing and implementing an array of assays and models to provide key biological insights and drive decision making in the drug discovery and development space.
Talk
Accelerating Functional Precision Oncology with MicroOrganoSpheres Technology
MicroOrganoSpheres (MOS) Technology accelerates functional precision oncology for therapeutics and diagnostics by enabling rapid, scalable and robust generation of patient-specific ex vivo tumor models with preserved tumor biology. The Xilis MOS Platform industrializes ex vivo patient tumor models for a variety of drug discovery, development and diagnostics applications.
Clinical & Research Tools Showcase:
Xilis
Xilis is an innovation-driven biotech developing its proprietary MicroOrganoSpheres® Technology for functional precision oncology. Xilis is harnessing and industrializing patient tumor models that retain patient-specific tumor biology to enable development of effective therapeutics and to guide them to the right patients at the right time.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Clinical & Research Tools Showcase will provide a 15-30 minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
